Heartflow announces Q3 earnings per share of 27 cents, surpassing consensus estimate of 24 cents.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 12 2025
0mins
Q3 Revenue Performance: Heartflow reported Q3 revenue of $46.28 million, exceeding the consensus estimate of $41.96 million, marking a 41% year-over-year growth.
CEO's Statement: John Farquhar, President and CEO, highlighted the strong performance driven by growth in the FFRCT business and an expanding installed base.
Physician Interest: There is increasing physician interest in Heartflow Plaque Analysis, which is expected to contribute to future growth following the establishment of broad commercial payor coverage.
Market Positioning: With ongoing business momentum and a strengthened balance sheet post-IPO, Heartflow is confident in its ability to expand its market leadership.
Analyst Views on HTFL
Wall Street analysts forecast HTFL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HTFL is 38.60 USD with a low forecast of 35.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 32.160
Low
35.00
Averages
38.60
High
40.00
Current: 32.160
Low
35.00
Averages
38.60
High
40.00
About HTFL
HeartFlow Inc. is a commercial-stage medical technology company that has pioneered the use of software and artificial intelligence (AI) to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). The Company’s novel HeartFlow Platform uses AI and advanced computational fluid dynamics to create a personalized three-dimensional (3D) model of a patient’s heart based on a single coronary computed tomography angiography (CCTA). Its AI-driven platform includes Roadmap Analysis, FFRCT Analysis and Plaque Analysis. The HeartFlow FFRCT Analysis and Plaque Analysis software assists physicians in diagnosing, managing and delivering precision care to patients with CAD. The RoadMap Analysis offers a highly intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
